A REVIEW ON FALLOPIAN TUBE CARCINOMA

Primary fallopian tube cancer is an uncommon condition that is challenging to treat. It is frequently included with primary ovarian and peritoneal carcinomas under the general heading of epithelial ovarian cancer. According to more recent data, ovarian epithelial malignancies may have their origins in a precursor in the fallopian tube. Platinum-based chemotherapy and surgical cytoreduction constitute the cornerstones of treatment. The ideal time for surgery and the best method for administering chemotherapy are hotly contested topics. Conventional intravenous regimens that are administered once every three weeks are contrasted with intraperitoneal and dose-dense regimens. Despite the ongoing discussions surrounding this topic, new targeted treatments have surfaced, such as bevacizumab and inhibitors of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP). Patients with BRCA1/2 gene mutations benefit most from PARP medicines, and using them has been demonstrated to increase patient survival. This article reviews the etiology, pathophysiology, symptoms, diagnosis and treatment of the disease.

Keywords: Fallopian tube carcinoma, high grade serous cancers, serous tubal intraepithelial carcinomas, Epithelial ovarian carcinoma (EOC).